NFKB1 and B-cell non-Hodgkin lymphoma: In an impressive demonstration, restoring negative feedback to NFκB by a myeloid cell-targeted miR-146a mimic that prevented excessive NFκB activation in myeloid cells not only alleviated lethal inflammation in a chimeric antigen receptor (CAR) T-cell-induced cytokine release syndrome model of xenotransplanted B-cell lymphoma, but was also cytotoxic to leukemia cells in vitro and in vivo; it inhibited NFκB target genes expression and thereby thwarted progression of disseminated HL-60 promyelocytic leukemia [68].